Abstract
T-cell-based immunotherapy of melanoma becomes ineffective when β2m-deficient tumor cells of a human leukocyte antigen (HLA) class I-negative phenotype grow out. We demonstrated that an early-acquired chromosomal deletion and subsequent inactivating gene mutation lead to β2m deficiency, suggesting that melanoma cells can genetically evolve to avoid being recognized by CD8(+) T cells.